Evidence map›Paper›PMID 35255979›Full record

ReviewStem cell research & therapy2022

Shining the light on clinical application of mesenchymal stem cell therapy in autoimmune diseases.

Saade Abdalkareem Jasim, Alexei Valerievich Yumashev, Walid Kamal Abdelbasset, Ria Margiana, Alexander Markov, Wanich Suksatan, Benjamin Pineda, Lakshmi Thangavelu, Seyed Hossein Ahmadi

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Stem cell research & therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
54citing papers in PubMed, 1 pooled it
12.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

54 citing papers in PubMed, 1 synthesis or guideline pooled it, 89 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Decoding Dental Stem Cell Aging: Mechanisms, Therapeutic Strategies, and Beyond.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 9 institutions in 9 countries.

Saade Abdalkareem JasimMedical Laboratory Techniques Department, Al-Maarif University College, Al-Anbar-Ramadi, Iraq.
Alexei Valerievich YumashevDepartment of Prosthetic Dentistry, Sechenov First Moscow State Medical University, Moscow, Russia.
Walid Kamal AbdelbassetDepartment of Health and Rehabilitation Sciences, College of Applied Medical Sciences, Prince Sattam Bin Abdulaziz University, Al Kharj, Saudi Arabia.
Ria MargianaDepartment of Anatomy, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia.
Alexander MarkovTyumen State Medical University, Tyumen, Russian Federation.
Wanich SuksatanFaculty of Nursing, HRH Princess Chulabhorn College of Medical Science, Chulabhorn Royal Academy, Bangkok, Thailand.
Benjamin PinedaDepartment of Neuroimmunology, National Institute of Neurology and Neurosurgery "Manuel Velasco Suarez" (INNN), 14269, Mexico City, Mexico.
Lakshmi ThangaveluCenter for Transdisciplinary Research ,Department of Pharmacology, Saveetha Dental College, Saveetha Institute of Medical and Technical Science, Saveetha University, Chennai, India.
Seyed Hossein AhmadiCellular and Molecular Research Center, School of Medicine, Tehran University of Medical Sciences, PO Box: 1417613151, Tehran, Iran. seyedh.ahmadi@yahoo.com.ORCID 0000-0002-8983-8584
Chulabhorn Hospital · THIndustrial University of Tyumen · RUInstituto Nacional de Neurología y Neurocirugía · MXPrince Sattam Bin Abdulaziz University · SASaveetha University · INSechenov University · RUTehran University of Medical Sciences · IRUniversity of Al Maarif · IQUniversity of Indonesia · ID

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The autoimmune diseases are associated with the host immune system, chronic inflammation, and immune reaction against self-antigens, which leads to the injury and failure of several tissues. The onset of autoimmune diseases is related to unbalanced immune homeostasis. Mesenchymal stem cells (MSCs) are multipotent cells which have capability to self-renew and differentiate into various cell types that exert a critical role in immunomodulation and regenerative therapy. Under the certain condition in vitro, MSCs are able to differentiate into multiple lineage such as osteoblasts, adipocytes, and neuron-like cells. Consequently, MSCs have a valuable application in cell treatment. Accordingly, in this review we present the last observations of researches on different MSCs and their efficiency and feasibility in the clinical treatment of several autoimmune disorders including rheumatoid arthritis, type 1 diabetes, multiple sclerosis, systemic lupus erythematosus, inflammatory bowel disease, autoimmune liver disease, and Sjogren's syndrome.

Indexed as

Autoimmune DiseasesLupus Erythematosus, SystemicMesenchymal Stem CellsMesenchymal Stem Cell TransplantationHumansImmunomodulationAutoimmune diseasesClinical applicationMesenchymal stromal cellStem cell therapy

Identifiers

PMID35255979
PMCPMC8900359
OpenAlexW4220893163

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.